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Elena Titova1,2*, Sigurd Steinshamn1,2, Bent Indredavik1,3,4 and Anne Hildur Henriksen1,2Abstract: Chronic obstructive pulmonary disease (COPD) is one of the main causes of morbidity and mortality
globally. In Trondheim in 2008 an integrated care model (COPD-Home) consisting of an education program,
self-management plan, home visits and a call centre for patient support and communication was developed.
The objective was to determine the efficacy of an intervention according to the COPD-Home model in reducing
hospital utilization among patients with COPD stage III and IV (GOLD 2007) discharged after hospitalization for acute
exacerbations of COPD (AECOPD).
Methods: A single centre, prospective, open, controlled clinical study comparing COPD-Home integrated care (IC)
with usual care (UC).
Results: Ninety-one versus 81 patients mean age 73.4 ± 9.3 years (57% women) were included in the IC group
(ICG) and the UC group (UCG) respectively, and after 2 years 51 and 49 patients were available for control in the
respective groups. During the year prior to study start there were 71 hospital admissions (HA) in the ICG and 84 in
the UCG. There was a 12.6% reduction in HA in the ICG during the first year of follow-up and a 46.5% reduction
during the second year (p = 0.01) compared to an 8.3% increase during the first year and no change during the
second year in the ICG. During the year prior to study start, the number of hospital days (HD) was 468 in the ICG
and 479 in the UCG. In the IC group, the number of HD was reduced by 48.3% during the first year (p = 0.01), and
remained low during the second year of follow-up (p=0.02). In the UC group, the number of HD remained unchanged
during the follow-up period. There was a trend towards a shorter survival time among patients in the ICG compared to
the UCG, hazard ratio 1.33 [95% CI 0.77 to 2.33].
Conclusion: Intervention according to the COPD-Home model reduced hospital utilization in patients with COPD III
and IV with a persisting effect throughout the 2 years of follow-up. However, there was a trend towards a shorter
survival time in the intervention group.
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The burden of chronic obstructive pulmonary disease
(COPD) is increasing, and globally COPD is predicted to
become one of the main causes of morbidity and mortality
in 2020 [1]. Acute exacerbations of COPD (AECOPD) are
major drivers for the worsening of health status in COPD,
and are important causes of hospital admissions (HA) and* Correspondence: elena.titova@ntnu.no
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unless otherwise stated.death [2]. Hospital admissions due to AECOPD have a
negative impact on health-related quality of life (HRQOL)
[3], are related to a greater decline in lung function and
exercise capacity [4] and a worsening of the COPD prog-
nosis [5,6]. Moreover, AECOPD are associated with an in-
creased number of visits to the general practitioners (GP)
or to the emergency department, and account for the
greatest proportion of the total COPD burden on the
health-care system. There is a direct relationship between
severity of COPD and the cost of care [1]. Improving pa-
tients’ and physicians’ understanding of the nature of
AECOPD, as well as the benefits of early treatment, has
been shown to improve the outcomes of therapy [7].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ising improvements in HRQOL and reduction in hospi-
talisation rates and duration of hospital stays due to
AECOPD [8]. However, it remains unclear which specific
components of the various interventions that have the
adequate power to induce a positive change, and what
are the characteristics of the patients who can benefit
from these interventions [9-11]. In Norway, local author-
ities provide free of charge home-care nursing services,
aiming to provide the necessary help required for pa-
tients with chronic diseases to maintain their HRQOL
by enabling them to stay in their homes for as long as
desired. The most frail and severely ill patients, such as
patients with severe COPD, are often users of these ser-
vices. The community-based medical services may repre-
sent a suitable basis for developing and establishing an
integrated care service for patients with severe COPD.
The Trondheim municipality and the Department of
Thoracic Medicine (DTM) at the Trondheim University
Hospital (TUH) have created a collaborative project to
develop and implement a model that integrates hospital-
and municipal-based services for COPD patients based on
local resources. The model was named the COPD-Home
integrated care model [12]. In the present paper, the
impact of the COPD-Home integrated care model on hos-
pital utilization after the two-year follow-up is presented.
Methods
Study design
The study was a prospective, open, single-centre inter-
vention study.
Participants
All participants were recruited from the DTM or the
Observation Unit (OU) at the TUH. The inclusion criteria
were: [1] admission due to AECOPD, [2] COPD (GOLD
stage III or IV, 2007), [3] living in the Trondheim munici-
pality, [4] an ability to communicate in Norwegian, and
[5] an ability to sign the informed consent form. The ex-
clusion criterion was: [1] any serious diseases that might
cause a very short lifespan (expected survival time less
than six months).
All eligible patients, who gave their consent to partici-
pate in the study, were consecutively enrolled before dis-
charge from the TUH. They were randomly allocated to
either integrated care (IC) or usual care (UC) based on
their address of permanent residence. The components
of the COPD-Home integrated care model and strategies
regarding implementation of the associated interventions
have previously been described in detail [11].
Allocation
The health-care services of Trondheim municipality are
organized into four districts. The population compositionof these four districts was fairly equal in age and sickness
panorama (i.e. the proportion with registered multi-
sickness or chronic diseases). In order to create two pairs
of districts with approximately equal numbers of citizens,
a pair-wise matching of districts was carried out, District
Pair 1 and District Pair 2. The number of citizens aged
55–75 years was 15,800 out of 83,000 in District Pair 1
and 15,200 out of 75,000 in District Pair 2, respectively. It
was decided by lottery that participants from District Pair
1 were assigned to the UC group, and participants from
District Pair 2 were assigned to the IC group.
Trondheim University Hospital (TUH) is the local
hospital for every person living in Trondheim. Nearly all
(98-100%) patients admitted to the DTM because of
AECOPD are referred as acute, not elective patients,
submitted by their GP, the GP on duty or by phoning
the emergency number.
The study protocol contained instructions concerning
information given to the patient at discharge and did not
include instructions regarding the decision to admit or
discharge patients. The study nurses contacted all pa-
tients hospitalized at the DTM or the OU because of
AECOPD and invited them to participate in the study
provided their home address was in the municipality of
Trondheim.
Intervention
All patients hospitalized with AECOPD were treated ac-
cording to the local and international guidelines. Usual
care was offered to the participants allocated to the UC
group and represented the standard procedure at dis-
charge from the TUH including an evaluation by the
treating physician of the patient's needs with respect to
an increase in the level of care from the home-care ser-
vices, rehabilitation or training or follow-up at the out-
patient clinic. Moreover, the patient was given written
information concerning the disease status and medica-
tion. The patient’s GP received a discharge summary
with a copy to the district home-care health service if
the patient was receiving any such services. The GPs
followed up the COPD patients and referred the patients
to a pulmonary specialist if necessary.
Home-care nursing services include help with personal
care, medicine dosage, injections, specific disease moni-
toring and observation, assistance with meals, help in
physical training and help in coordinating aid efforts
with other services and emergency assistance, as well as
supervision regarding the using of security alarms. The
participants in the UC group were evaluated by a study
coordinator (a specialist nurse) at discharge from TUH
and during scheduled visits in their own homes after
six-, 12- and 24 month of follow-up. The specialist
nurses are registered nurses with enhanced competence
in respiratory medicine.
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COPD-Home model was offered to the participants al-
located to the IC group. The core elements of the
COPD-Home model were: [1] a call centre staffed by
three specialist nurses for support and communication
with patients and home-care nurses, and coordination
between the various levels of care. The patients were
routinely (at least once a month) contacted by the special-
ist nurses, and they were supported by telephone calls dur-
ing COPD exacerbations; [2] an education session for
home-care nurses: a three-hour theoretical session cover-
ing several aspects of COPD and two days of practice at
the DTM; [3] an interactive 15-minute e-learning program
for the patients concerning the management of COPD; [4]
an individualized self-management plan introduced to the
patient at discharge by the treating doctor and a specialist
nurse. The plan contains tools for the monitoring of
symptoms and written instructions for the self-initiation
of prednisone and/or antibiotics, provided specific symp-
toms have been recorded; and [5] joint visits at the pa-
tients home by the specialist nurse (together with the
home-care nurse for participants receiving home services)
at approximately three days, 14 days, six months,
12 months and 24 months post-discharge. The major
components of these visits were repetition of the core ele-
ments of the education program, making necessary
changes in the patient’s treatment plans and the reinfor-
cing of specific health behaviors. The patient’s GP was also
invited to participate in these visits.
All participants included in the COPD-Home study
were free to use all available medical services, including
their GPs.
Outcome measures
The primary outcomes were: [1] Number of hospital ad-
missions caused by AECOPD (HA) and [2] number of
in-hospital days (HD) due to AECOPD. HA and HD due
to AECOPD include admittances where pneumonia was
diagnosed during the hospital stay. The HA and HD was
assessed in three time periods: during the one year prior
to the study enrolment, and during the first- and second
year of follow-up. Data concerning HA and HD were col-
lected from the hospital registry database’s medical charts.
The International Classification of Disease (ICD 10) was
used to classify the diseases that caused the hospitalization.
A HA was defined as a hospitalization due to any acute
worsening of COPD, including pneumonia (ICD-10: J44.09
or J13-18 + J44.0-9).
Data from patients who completed a minimum of two
years of follow-up were included in the analysis. The med-
ical records from the one-year period prior to the study
start and the index hospitalizations were reviewed to iden-
tify the Charlson’s co morbidities by using the ICD-10
coding algorithm [13-15]. Conditions that occurred orwere diagnosed during the follow-up period were not in-
cluded. The age-adjusted Charlson Comorbidity Index
(CCI) was calculated by use of an online calculator (farma-
cologiaclinica.info/scoring-tools/).
Baseline characteristics (age, gender, forced expiratory
volume in one second (FEV1), arterial blood gases, the
body mass index (BMI) and baseline data on co-morbidity,
medical treatment, lifestyle factors, as well as patient char-
acteristics and disease status after one and two years of
follow-up, were collected from the study reports. Data
regarding mortality were collected from medical records
at the TUH and the National Cause of Death Registry,
Statistics Norway.
Ethics
The study was approved by the Regional Ethics
Committee (REC), and the participants gave their
written informed consent. Mortality was not a primary
outcome of the study, but when the patients’ data were
analysed after two years of follow-up, an increased
number of deaths were registered among the patients in
the IC group compared to the UC group. The REC was
informed, and the study was s temporarily stopped. Data
on the causes of death were analysed, and the REC
concluded that the increased number of deaths in the
IC group was not related to the COPD-Home interven-
tion, but could be explained by pre-study poorer health
status and higher age. The study was reopened after a
break of eight months, and the project manager decided
not to continue the intervention program, but contin-
ued the registration of observations in both groups until
all the participants had been followed- up for three
years.
Statistical analysis
Demographic characteristics registered at both baseline
and follow-up were reported as mean ± SD. Data with a
normal distribution were compared using an independ-
ent sample t-test while categorical variables were ana-
lysed using the chi-square test.
The percentage of the differences in the number of
HA and HD was calculated by dividing the absolute
difference between the values from the year prior to the
study start and the values after one or two years of
follow-up in the IC and UC groups respectively.
Due to the skewed distribution, HA and HD were
summarized using medians and inter-quartile ranges
(IQR). Comparisons of HA and HD between the UC
and IC groups were performed using non-parametric
techniques.
Patients were categorized according to the frequency
of their HA, using HA category 1 (≤1 HA per year) and
HA category 2 (≥2 HA per year). The differences in the
proportions of individuals in the HA categories during
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the chi-squared test, and the results were presented as
percentages with corresponding p-values.
A univariate survival analysis for the different demo-
graphic and clinical variables at the study start was
performed according to the Kaplan Meier procedure,
whereas tests for the differences in the survival curves
for the different categories of variables were performed
with Mantel-Cox statistics. Variables with a significant
effect on survival in the univariate analysis were further
analysed using the multivariate Cox proportional haz-
ard regression model to calculate the hazard ratios and
95% confidence intervals for risk factors. Survival
analyses were performed with total mortality (all causes
of death) as the endpoint. P-values < 0.05 were consid-
ered to be statistically significant, and all statistical
analyses were performed using PASW Statistics 19,
SPSS Inc. Chicago.
Results
Between March 2008 and November 2011, a total of 199
patients were invited to participate in the study. Of
those, 27 patients declined to participate, and 172 pa-
tients were randomly allocated to the IC group (n = 91)
or the UC group (n = 81), respectively. After two years ofFigure 1 Schematic presentation of the study profile over two years.follow-up, a total of 100 patients (58% of the included
patients), 51 patients in the IC group and 49 patients in
the UC group, were available for evaluation (Figure 1).
There were no significant differences in baseline char-
acteristics between the IC and the UC groups, but when
comparing those who died during follow-up with those
who were still alive after two years, those who died had
a significantly higher PaCO2 and lower BMI at baseline
(Table 1). Those who died during follow-up also had sig-
nificantly more HA and HD during the year prior to
study start.
During the year prior to study start, there were 71 HA
at the DTM in the IC group and 84 in the UC group.
When comparing the number of HA at the DTM during
follow-up with the year prior to study start, there was a
12.6% reduction in the IC group during the first year of
follow-up and a 46.5% reduction during the second year
(p = 0.01). In the UC group there, was an 8.3% increase
in HA during the first year and no change in the number
of HA during the second year of follow-up (Table 2).
During the year prior to study start, the number of
HD was 468 in the IC group and 479 in the UC group
(Table 2). In the IC group, the number of HD was
reduced by 48.3% during the first year (p = 0.01),
and remained low during the second year of follow-upIC: integrated care; UC: usual care.
Table 1 Baseline characteristics of participants in the integrated and usual care groups according to follow-up status
Died during follow-up Alive after two years of follow-up
IC group UC group p-value IC group UC group p-value p - value
n = 35 n = 21 IC v UC n = 51 n = 49 IC v UC Died v Alive
Age, years, mean ± SD 76.4 ± 9.6 74.7 ± 8.0 0.5 72.5 ± 9.0 73.1 ± 9.4 0.7 0.09
Sex: female, n (%) 20 (57) 13 (62) 0.7 29 (57) 27(55) 0.8 1.0
Living arrangements:
Living alone, n (%) 15 (42.9) 12 (57.1) 0.3 29 (56.9) 22 (44.9) 0.2 0.7
Receiving home-care services, n (%) 24 (58.5) 17 (41.5) 0.3 24 (48.0) 20 (40.8) 0.5 0.5
FEV1, litres, mean ± SD 0.81 ± 0.4 0.75 ± 0.3 0.5 0.92 ± 0.35 0.84 ± 0.34 0.3 0.07
FEV1%, mean ± SD 32.3 ± 10.5 31.7 ± 9.9 0.9 34.9 ± 9.4 33.4 ± 9.2 0.4 0.2
PaO2, kPa, mean ± SD 8.04 ± 1.3 8.7 ± 1.7 0.1 9.0 ± 1.4 8.7 ± 1.2 0.3 0.3
PaCO 2,kPa, mean ± SD 6.1 ± 1.3 6.2 ± 1.3 0.9 5.6 ± 0.8 5.7 ± 1.0 0.1 0.008
GOLD stage 4, n (%) 14 (40) 11 (52) 0.4 20 (39) 22 (45) 0.6 0.5
BMI, kg/m2, mean ± SD 21.6 ± 4.7 22.1 ± 6.5 0.8 23.9 ± 5.4 23.9 ± 4.6 0.9 0.05
Current smoker, n (%) 10 (28.6) 11 (52.4) 0.08 18 (35.3) 15 (30.6) 0.8 0.6
Inhaled medication:
LAMA 13 (37.1) 11 (52.4) 0.3 20 (39.2) 25 (51) 0.2 0.8
LABA + ICS 25 (71.4) 17 (81.0) 0.4 36 (70.6) 35 (71.4) 0.9 0.6
HA one year prior to study start, median (IQR) 2 (1, 3) 2 (1, 3) 0.6 1.0 (1, 1) 1.0 (1, 2) 0.03 0.01
HD one year prior to study start, median (IQR) 9 (6, 22) 11 (7.5, 18.5) 0.9 7 (4, 11) 8 (5, 13) 0.2 0.003
IC: integrated care; UC: usual care; FEV1: forced expiratory volume in one second; FEV1%: FEV1% of predicted value; PaCO 2: partial pressure of carbon dioxide in
the arterial blood; PaO 2: partial pressure of oxygen in the arterial blood; BMI: body mass index; LAMA: long- acting muscarinic receptor antagonist; LABA: long-acting
β2- agonist; ICG: Inhaled Corticosteroids; AECOPD: acute exacerbation of COPD; HA: hospital admissions due to AECOPD; HD: hospital days due to AECOPD.
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unchanged during the follow-up period. During the year
prior to study start, the percentages of patients in HA
category 1 (≤1 HA per year) and HA category 2 (≥2 HA
per year) were similar in both the IC and the UC group.
During the first year of follow-up, eight (15.7%) patients
changed from HA category 2 to HA category 1 in the IC
group, while two patients (4%) changed from HA cat-
egory 1 to HA category 2 in the UC group, p = 0.01
(Table 3). During the second year of follow-up, there
was still a trend towards a higher percentage of patients
in HA category 1 in the IC group compared to the UC
group (Table 3).
There were no significant differences in the number of






HA (N), IC group 71 62 - 12.6
HA (N), UC group 84 91 +8,3
HD (N), IC group 468 242 - 48.3
HD (N), UC group 479 488 +1.8
P -value*: the year before study start versus the first year of follow-up.
p -value**: the year before study start versus the second year of follow-up.
IC: integrated care; UC: usual care; HA: hospital admissions due to AECOPD; HD: hosUC group at baseline or within the groups during the
follow-up period, but there was a trend towards a reduc-
tion in the number of current smokers in the IC group
from 18 (35.5%) at baseline to 16 (31.4%) after
12 months and to 14 (27.5%) after 24 months. In the
UC group the corresponding numbers were 15 (30.6%)
at baseline, unchanged after 12 months and 13 (26.5%)
after 24 months.
There was a non-significant increase in the number of
patients receiving long-acting muscarinic receptor antag-
onist (LAMA) during 24 months of follow-up in the IC
group from 20 (39.2%) to 25 (49.05%) and a trend to-
wards a reduction in the UC group from 25 (51.0%) to
23 (46.9%). At baseline 36 (70.6%) in IC group versus 35
(71.4%) in UC group received a combination of long-ollow-up period
) p – value* Second year
of follow-up
Differences (%) p - value**
0.13 38 - 46.5 0.01
0.61 84 0 0.33
0.01 244 - 47.8 0.02
0.19 466 - 2.7 0.20
pital days due AECOPD.
Table 3 Changes in the proportions of individuals in the two hospital admission categories during follow-up
IC group (n=51) UC group (n=49) p-value
HA category 1 2 1 2
The year prior to study start, n, (%) 40 (78.4) 11 (21.6) 39 (79.6) 10 (20.4) 1.00
The first year of follow-up, n (%) 48 (94.1) 3 (5.9) 37 (75.5) 12 (24.5) 0.01
The second year of follow-up, n (%) 44 (86.3) 7 (13.7) 37 (75.5) 12 (25.4) 0.21
HA: hospital admissions due to AECOPD; HA category 1: ≤ 1 HA per year;
HA category 2: ≥ 2 HA per year.
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costeroids (ICS), and there were no significant differ-
ences either between the IC and the UC group or within
the groups during the follow-up period.
During the two-year follow-up period, there was a
trend towards an increased number of deaths in the IC
group compared to the UC group, 35 (38.5%) and 21
(25.9%), respectively. In both groups, the most frequent
primary cause of death was AECOPD and/or pneumo-
nia, 22 patients in the IC group and 10 patients in the
UC group respectively (Table 4).
The univariate survival analysis for the different demo-
graphic and clinical variables showed that survival time
was significantly related to baseline age (p = 0.04), BMI
(p = 0.006), PaCO 2 (p = 0.02) and receiving home-care
nursing (p = 0.001). The shortest survival time was found
in patients receiving home-care nursing (p = 0.001), with
a high age (≥80 years), a low BMI and a high PaCO2
(Table 5). The longest survival time was found in pa-
tients 70–79 years old, with a PaCO 2 < 6.1 and a BMI
18–25. In multivariate survival analysis, mortality was
significantly related to a lower BMI (p = 0.008) and re-
ceiving home-care nursing (p = 0.017), Table 6.
Although the difference was not statistically signifi-
cant, there was a trend towards a shorter survival time
among the participants in the IC group compared to
those in the UC group with a hazard ratio of 1.33 [95%
CI 0.77 to 2.33].
At the department of thoracic medicine (DTM) at
TUH the extra costs attached to the COPD-HomeTable 4 All-cause mortality during two years of follow-up
Causes of death/group IC group UC group P-value*
(n=35) (n=21)
AECOPD and pneumonia, n (%) 22(62.8) 10(47.6) 0.26
Cardiovascular diseases, n (%) 4(11.4) 4(19) 0.43
Sepsis, not related to
infections in lungs, n (%)
4(11.4) 2(9.5) 0.82
Cancer, n (%) 3(8.6) 1(4.8) 0.59
Mors subita, nonviolent,
causa ignota, n (%)
2¤(5.7) 4¤(19) 0.12
¤Death certificates are not made public; *statistically significance IC group
versus UC group.
IC: integrated care; UC: usual care.intervention amounted to roughly one 100% nurse pos-
ition (workdays from 8 am to 3 pm) during four years
including training of the home care nurses. During the
inclusion period the Municipality of Trondheim spent a
total of ca 40.000 € in extra hours for home care nurses
attending training programs at the DTM.Discussion
The aim of the present study was to evaluate the long-
term impact of the integrated care intervention accord-
ing to the COPD-Home model on hospital utilization in
patients with severe and very severe COPD. The core el-
ements of the COPD-Home model were disease-specific
education, an individualized self-management plan, joint
visits in the patient’s home by a specialist nurse, and a
call centre support. This intervention model includes at
least four of the six necessary key components of the
ATS chronic care model [16]. In addition, the COPD-
Home model contains dimensions specifically targeted
at multi-morbid COPD patients, such as coordinating
services between different health-care levels and health-
care providers, including nursing homes.
The principal findings of the present study were a re-
duction in the number of patients with frequent HA and
a reduced number of both HA and HD during follow-up
in the IC group compared to the UC group. While the
decrease in the number of HD was more pronounced
during the first year of follow-up, the decrease in the
number of HA became significant only during the sec-
ond year of follow-up. In contrast, in the UC group
there was no significant changes in the number HA or
HD during the follow-up period.
When comparing our results with results from previ-
ous studies on integrated care interventions among
COPD patients, we found that the interpretation is ham-
pered by differences in inclusion criteria, the scope of
the various interventions and the duration of the
follow-up period. In a study by Bourbeau and colleagues
from 2003 [17], the intervention program included a
self-management plan supported by an experienced case
manager and communication by regular telephone con-
tact. In the intervention group, they found an improve-
ment of the patient’s health status, 39.8% reduction in
Table 5 Univariate survival analysis for the different
demographic and clinical variables







IC group 86 35 12.0 0.17
UC group 70 21 19.0
Sex: 0.71
Male 67 23 17.0
Female 89 33 13.0
Age (yrs): 0.04
<70 49 14 18
70-79 54 16 21
=>80 53 26 9
BMI: 0.006
<18 20 13 3.0
18-25 95 31 16.0
>25 41 12 23.0
FEV1: 0.34
<0,5L 11 4 13.0
0,5L-1,0L 103 41 12.0
>1,0 41 11 24.0
FEV1%: 0.58
<30 58 23 16.0
30 -54 97 33 14.0
PaCO 2, kPa: 0.02
<=6.1 108 32 18.0
>6.1 47 23 11.0
PaO 2, kPa: 0.17
<=8.0 53 23 12.0
>8.0 103 33 17.0
Civil status: 0.72
Living alone 78 16 16.0
Living with partner 78 12 12.0
Home-care nursing: 0.001





1 - 3 32 9 13.0
4 - 6 94 33 17.0
7 - 10 30 14 8.0
IC: integrated care; UC: usual care; BMI: body mass index; FEV1: forced expiratory
volume in one second; FEV1%: FEV1% of predicted value; PaCO 2: partial pressure
of carbon dioxide in the arterial blood; PaO 2: partial pressure of oxygen in the
arterial blood.
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in hospital admissions for other health problems. While
in the present study only patients with a very short life
expectancy were excluded, Bourbeau and colleagues did
not include patients with a history of congestive heart
failure or asthma as well as patients who had recently
attended a respiratory rehabilitation program or pa-
tients in long-term care facilities. Moreover, in contrast
to the present study where patients were included dur-
ing a hospital stay because of an AECOPD, in the study
by Bourbeau only patients with a stable COPD for at
least four weeks were enrolled.
Casas and colleagues recruited exacerbated COPD pa-
tients at discharge from hospital to a standardized inte-
grated care intervention. They found a significantly
lower re-hospitalization rate during the 12 months of
follow-up in the intervention group compared to the
control group, 1.5 ± 2.6 versus 2.1 ± 3.1 respectively [18].
In contrast to the present study, patients with severe co
morbidities were excluded from the study by Casas.
However, the overall percentages of deaths during the
12 months of follow-up were rather similar, 19% versus
16% in the intervention and control groups respectively.
Moreover, in 2010, Rice and colleagues reported the re-
sults from an intervention study in which patients with
severe COPD received one education session, an action
plan for self-treatment and monthly telephone calls from
a case manager [19]. After one year of follow-up, they
found a 41% reduction in the hospitalization rate and
the number of emergency visits for COPD among the
patients in the intervention group. The positive effect of
their disease management intervention is very similar to
the results achieved in the present study, but the num-
ber of deaths during the one-year follow-up period was
relatively lower and more evenly distributed between the
intervention group (9.7%) and the control group (12.9%).
The differences in mortality between the two studies may
be explained by a higher age and the more severe disease
status at inclusion among the participants in the present
study compared to the study by Rice and colleagues.
More recently, Fan and colleagues evaluated the effi-
cacy of a comprehensive care management program in
reducing the risk for COPD related hospitalizations [20].
The authors were unable to show any reduction in hos-
pital admissions, and surprisingly the all causes mortality
was significantly higher among the patients in the inter-
vention group compared to those in the control group,
HR: 3.00 (95% CI 46–6.17). The authors did not find a
satisfactory explanation for the increase in HR, but
deaths due to COPD accounted for the largest difference
between the two groups. Also, it was revealed that pa-
tients in the intervention group did not take medication
any sooner in the event of an AECOPD than the patients
in the usual care group. As in the present study, there
Table 6 Multivariate survival analysis for the different demographic and clinical variables












1 1.33 (0.77-2.33) 1 0.75 (0.43-1.32) 0.80 (0.40-1.66) 0.57 (0.30-1.13) 1 3.09 (1.55-6.17) 1 0.96 (0.47-1.99) 1 1.81 (1.01-3.24) 1 2.10 (1.10-4.04)
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Fan and colleagues the patients’ education program was
more extensive. Moreover, the qualifications of the case
managers ranged from nurse practitioners to medical
doctors while in the present study only specialist nurses
acted as case managers.
When interpreting the results of the COPD-Home
intervention, we found that hospital admissions were re-
duced only in a proportion of the patients.
In COPD-Home highly qualified specialist nurses were
available for support, guidance and education at a low
threshold basis, for both patients and home care nurses.
These essential parts of the intervention may have
encouraged behavioral changes among the patients.
Bourbeau and colleges have addressed the importance of
achieving behavioral changes among the patients as a
prerequisite to succeed in improving the health out-
comes [21,22]. Also, the specialist nurses’ easy access to
discuss their actions with a pulmonologist may have
been an important factor in providing a more custom-
ized treatment for the patients. Hence, we speculate that
the reduction in hospital utilization in the integrated
care group was a result of better knowledge, skills and
confidence to manage their own healthcare. However,
due to the restricted number of participants it is beyond
the scope of the present study to conclude what particu-
lar parts of the intervention that led to the reduced hos-
pital utilization.
Information concerning the number and duration of
the COPD exacerbations, as well as the time from onset
of symptoms until the start of self-initiated treatment is
insufficient due to the many incomplete registrations in
“My COPD book”. Therefore, it cannot be concluded
why the intervention was successful in some patients
and ineffective in others. However, one hypothesis is that
some patients had knowledge and confidence before-
hand, and when given the intervention with education
and supervision they became prepared to play a more ac-
tive role in managing their own health resulting in im-
proved disease control [23]. On the other hand, it is likely
that patients who were not capable of, or motivated for
such changes did not benefit from an intervention pro-
grams relaying on active involvement from the patients
themselves [24]. Also, it might be difficult for patients with
several co morbidities and patients of advanced age to dis-
tinguish the origin of their various symptoms, such as
shortness of breath or pain [25,26].
The COPD-Home intervention was ambitious, and
some measures were not successful. The GPs did not
find time to meet with the specialist nurses in the pa-
tients homes after discharge, and a substantial number
of persons were involved in the home-care services for
each patient because of the continuous change of work
hours among the home care nurses. As a result not allthe involved home care nurses managed to attend the
COPD-Home education program. We therefore assume
that the qualifications and skills of the home-care nurses
varied substantially resulting in differences in their guid-
ance of the patients with respect to adherence to their
action plans [23].
COPD is a multi-component disease in its nature. Also,
COPD patients with co-morbidities such as cancer or car-
diovascular disorders may require a specific integrated
pathway of health care across several medical specialties
[27]. More knowledge is needed concerning what it takes
for particularly multi-morbid, older patients to become in-
formed, motivated, and involved in their own healthcare. In
future studies, these aspects need to be taken into account
in order to construct more facilitated intervention pro-
grams that contain schemes for the registration of complex
symptoms and alternative treatment strategies [24].
Conclusions
An intervention in accordance with the COPD-Home
integrated care model among patients with severe COPD
was shown to be effective in reducing the number of pa-
tients with frequent hospital admissions and the number
of hospital admissions as well as in-hospital days. Hence,
the intervention contributed to a reduction in hospital
utilization during the two-year follow-up period. Even
so, we may not be able to claim generalizability of the
results because of the relatively small number of partici-
pants with a considerable variety of co-morbidities and
health-care needs. Additionally, the finding of a trend to-
wards increased mortality in the intervention group that
could not be fully explained by pre-study health differ-
ences further emphasizes that our results must be inter-
preted with caution.
The study highlights the necessity for careful individu-
ally designed self-management programs. In future re-
search, subsets of COPD patients that are most receptive
to such interventions need to be identified, and the effect-
iveness of intervention programs targeting complex co-
morbid patients should be studied.
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